UCB (OTCMKTS:UCBJY) Shares Gap Down – Here’s Why

UCB SA (OTCMKTS:UCBJY)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $142.74, but opened at $134.70. UCB shares last traded at $134.58, with a volume of 784 shares.

Analyst Upgrades and Downgrades

A number of research analysts have commented on UCBJY shares. Zacks Research raised shares of UCB from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a research note on Monday, June 22nd. Finally, Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, UCB currently has a consensus rating of “Moderate Buy”.

UCB Stock Down 1.3%

The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The business’s 50 day moving average is $143.97 and its 200 day moving average is $147.95.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.